Devyser wins tender in Italy worth approximately SEK 5.7 million – doubling test volumes compared with previous agreement
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
News
News | November 17, 2022
Conventional genetic testing for thalassemia requires the use of several techniques, leading to long turnaround times. The single-tube NGS solution from Devyser can replace all these methods and provide the full information needed for a complete genetic profile within a day. This reduces the time of the laboratory workflow by weeks and the complete clinical workflow by up to a month.
Dr. Thessalia Papasavva at the Cyprus Institute of Neurology and Genetics is performing genetic testing for thalassemia in Cyprus, both for diagnostics and as part of the national screening programs. She has pioneered next-generation genetic testing for Thalassemia by fully implementing the NGS solution in their routine lab. She will share her experiences in this webinar.
During the webinar we will discuss:
Webinar details
Date: Tuesday, November 29th, 2022
Time: 10-10:30 am CET I 10-10:30 am PT
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
Read More
Devyser announced that One Lambda™ Devyser Accept cfDNA, its test for monitoring kidney transplant...
Read More
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial...
Read More
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More